Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy

被引：0
|
作者：
Michalaki, V.
Gennatas, S.
Gennatas, C. G.
机构：
[1] Univ Athens, Arete Hosp, Athens, Greece
[2] Univ Athens, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5116
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
    Abe, Marina
    Shoji, Tadahiro
    Chiba, Yohei
    Takatori, Eriko
    Kaido, Yoshitaka
    Nagasawa, Takayuki
    Kagabu, Masahiro
    Takahashi, Fumiaki
    Aida, Takeshi
    Baba, Tsukasa
    ANTICANCER RESEARCH, 2023, 43 (03) : 1265 - 1272
  • [42] Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
    Elshebeiny, Mohamed
    Almorsy, Walid
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2016, 28 (03) : 183 - 189
  • [43] A study of weekly Taxol® in patients with recurrent platinum resistant ovarian cancer.
    Kaern, J
    Tropé, C
    Baekelandt, M
    Kristensen, GB
    Gundersen, G
    ANNALS OF ONCOLOGY, 2000, 11 : 85 - 85
  • [44] Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.
    Liao, John B.
    Gwin, William Rayford
    Urban, Renata
    Hitchcock-Bernhardt, Katie
    Coveler, Andrew L.
    Higgins, Doreen
    Childs, Jennifer S.
    Shakalia, Hania
    Stanton, Sasha E.
    Tinker, Anna
    Wahl, Tanya A.
    Ancheta, Richard G.
    McGonigle, Kathryn F.
    Dai, James
    Disis, Mary L.
    Goff, Barbara Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Efficacy of platinum-based chemotherapy in platinum-resistant ovarian cancer: A systematic review with pooled analysis of outcomes
    Rumyantsev, A.
    Tyulyandina, A.
    Fedyanin, M.
    Pokataev, I.
    Glazkova, E.
    Nikulin, V.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S625 - S626
  • [46] Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study
    Ghamande, SA
    Piver, MS
    JOURNAL OF SURGICAL ONCOLOGY, 1999, 72 (03) : 162 - 166
  • [47] EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER
    Pinto, R.
    Monteiro, S.
    Lima, B.
    Lopes, A. R.
    Abreu, M.
    Ferreira, M.
    Sousa, S.
    Redondo, P.
    Pereira, D.
    Savva-Bordalo, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A271 - A271
  • [48] EXPERIENCE OF WEEKLY DOSE DENSE CARBOPLATIN AND PACLITAXEL IN PLATINUM RESISTANT OVARIAN CANCER
    Roxburgh, P.
    Sharma, R.
    Brooks, A.
    Reed, N.
    Gabra, H.
    Glasspool, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 212 - 212
  • [49] Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial
    Cowan, Mathew
    Swetzig, Wendy M.
    Adorno-Cruz, Valery
    Pineda, Mario J.
    Neubauer, Nikki L.
    Berry, Emily
    Lurain, John R.
    Shahabi, Shohreh
    Taiym, Deanna
    Nelson, Valerie
    O'Shea, Kaitlyn Lucrezia
    Kocherginsky, Masha
    Matei, Daniela
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 57 - 63
  • [50] Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy
    Jeerakornpassawat, Dhammapoj
    Suprasert, Prapaporn
    OBSTETRICS & GYNECOLOGY SCIENCE, 2020, 63 (01) : 55 - 63
12345